Diabetes and cirrhosis: current concepts on diagnosis and management

L Castera, K Cusi - Hepatology, 2023 - journals.lww.com
Type 2 diabetes mellitus is often associated with cirrhosis as comorbidities, acute illness,
medications, and other conditions profoundly alter glucose metabolism. Both conditions are …

Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin

J Rosenstock, SC Bain, A Gowda, E Jódar… - … England Journal of …, 2023 - Mass Medical Soc
Background Insulin icodec is an investigational once-weekly basal insulin analogue for
diabetes management. Methods We conducted a 78-week randomized, open-label, treat-to …

2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction: a report of the American College of Cardiology …

MM Kittleson, GS Panjrath, K Amancherla… - Journal of the American …, 2023 - jacc.org
The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

[HTML][HTML] Insulin–pharmacology, therapeutic regimens, and principles of intensive insulin therapy

T Donner, S Sarkar - 2015 - europepmc.org
Since the introduction of insulin analogs in 1996, insulin therapy options for patients with
type 1 and type 2 diabetes have expanded. Insulin therapies are now able to more closely …

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised …

VR Aroda, J Aberle, L Bardtrum, E Christiansen… - The Lancet, 2023 - thelancet.com
Background Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed
to investigate a new formulation of oral semaglutide at higher investigational doses versus …

Pragmatic Trial of Hospitalization Rate in Chronic Kidney Disease

MA Vazquez, G Oliver, R Amarasingham… - … England Journal of …, 2024 - Mass Medical Soc
Background Despite the availability of effective therapies for patients with chronic kidney
disease, type 2 diabetes, and hypertension (the kidney-dysfunction triad), the results of large …

The glucose management indicator: time to change course?

E Selvin - Diabetes care, 2024 - Am Diabetes Assoc
Laboratory measurement of hemoglobin A1c (HbA1c) has, for decades, been the standard
approach to monitoring glucose control in people with diabetes. Continuous glucose …

Personalized glycated hemoglobin in diabetes management: closing the gap with glucose management indicator

TC Dunn, Y Xu, RM Bergenstal, W Ogawa… - Diabetes Technology …, 2023 - liebertpub.com
Glycated hemoglobin (HbA1c) has played a central role in the management of diabetes
since the end of the landmark Diabetes Control and Complications Trial 30 years ago …

Association between diabetes technology use and glycemic outcomes in adults with type 1 diabetes over a decade

KE Karakus, HK Akturk, GT Alonso… - Diabetes …, 2023 - Am Diabetes Assoc
OBJECTIVE To evaluate change in mean clinic HbA1c from 2014 to 2021 with diabetes
technology use in adults with type 1 diabetes. RESEARCH DESIGN AND METHODS In this …

Care of young children with diabetes in the childcare and community setting: a statement of the American Diabetes Association

C March, J Sherman, RR Bannuru, A Fischer… - Diabetes …, 2023 - Am Diabetes Assoc
Diabetes management in children extends from the home to other settings where children
spend a significant portion of their waking hours. For young children (generally, aged< 5 …